Judge Dismisses FTC’s Schering-Plough Case
- Share via
A judge dismissed Federal Trade Commission charges that Schering-Plough Corp. and Upsher-Smith Laboratories Inc. colluded to set prices for a blood pressure drug.
The decision by an FTC administrative law judge is a defeat for the FTC’s concerted push against what it sees as a pattern of anti-competitive practices within the drug industry that is keeping cheap generics off the market.
The FTC had alleged that Schering-Plough, the maker of K-Dur 20, illegally paid pharmaceutical firms millions of dollars to induce them to delay launching generic versions of the drug.
Shares of Schering-Plough fell $1.14 to $22.36 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
